Lancet Case Report, Which Served as the Basis for Neonatal Morphine Addiction Regulations, Officially Retracted Amid Data Manipulation Allegations

Background
In the medical community, there is a representative case in which a single case report completely transformed global health policies and drug prescription guidelines. A notable example is the paper published in 2006 in the international journal The Lancet by Professor Gideon Koren's research team at The Hospital for Sick Children in Toronto, Canada. At the time, the researchers reported that a 13-day-old newborn died of fatal morphine poisoning after a breastfeeding mother took codeine prescribed as a painkiller. The researchers explained that this was because the mother was an ultra-rapid metabolizer with abnormally high cytochrome P450 2D6 (CYP2D6) enzyme activity. The analysis suggested that codeine was rapidly converted to morphine in the mother's body and then secreted into breast milk at high concentrations, reaching the infant.
This report is cited as a textbook case in the field of pharmacogenomics and has prompted action from regulatory authorities worldwide. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) updated drug safety warnings based on this evidence, either fully prohibiting or strictly limiting the administration of codeine to nursing mothers. Protocols for pain management in postpartum women have been completely restructured. However, in recent years, whistleblowers have begun to allege serious errors and distortions in the authenticity of toxicological data released at that time and in the measured concentrations of morphine in patients' blood and breast milk.
Key Findings
The Lancet editorial office has officially received allegations regarding the 2006 case report by Professor Koren’s research team involving manipulation of toxicological data, inappropriate authorship, and violations of research ethics. On February 3, 2026, the editorial office published an Expression of Concern regarding the paper and transferred the investigation authority to the Research Integrity Office of The Hospital for Sick Children in Toronto, Canada. An independent investigation committee launched a formal investigation, cross-referencing archived raw data, experimental records, and laboratory reports written at the time.
The investigation committee confirmed that key toxicological values had been manipulated and notified the journal's editorial board of the findings. It was clearly revealed that the morphine concentrations in breast milk and postmortem serum levels reported by the researchers did not match the values derived from the actual analytical equipment, or were artificially altered. Furthermore, allegations regarding eligibility issues in the process of listing co-authors on the paper and violations of clinical ethics approval procedures were included in the complaint. However, because former Professor Koren, who played a leading role, was unable to provide meaningful statements or participate in explanation procedures due to deteriorating health and other reasons, the investigation into ethical and authorship concerns could not be formally concluded. The Lancet editorial board has officially retracted the paper, determining that its academic credibility is completely undermined given that manipulation of the core toxicological data has been proven.
Implications and Outlook
This retraction decision serves as a painful lesson for the medical community and regulatory science. The fact that a single case, which served as a cornerstone for numerous guidelines for 20 years, was based on fabricated data reveals structural flaws in the research integrity verification system. Of course, the biological mechanism itself—the difference in metabolic rates due to CYP2D6 genetic variants and the risk of drug side effects—is not invalidated. The pharmacogenomic principles derived from other mechanistic studies and pharmacokinetic modeling remain valid.
However, the quantitative scientific evidence regarding whether codeine, prescribed at routine levels for mothers, can accumulate to fatal concentrations in breastfeeding infants necessitates a fundamental re-examination. Regulatory authorities are faced with the task of reviewing whether to amend the excessive regulatory provisions, which were previously established based solely on this paper, in light of the latest evidence. Within the academic community, there are strong calls to significantly strengthen the post-publication monitoring system for single clinical reports that rely on the authority of prestigious institutions while data access is restricted.
On Feb 3, 2026, The Lancet published an Expression of Concern1 for a 2006 Case Report by Gideon Koren and colleagues,2 having received new allegations of falsification of toxicological data, authorship issues, and ethical concerns. These new allegations were referred to the Research Integrity Office of The Hospital for Sick Children, Toronto, ON, Canada, for a new formal investigation. We have now received the outcome and conclusion of this investigation. The authorship issues and ethical concerns could not be fairly investigated as a meaningful participation of Gideon Koren was unlikely to be possible.
This paper retraction has direct implications for the clinical field of postpartum pain management and the pharmacogenomic testing market. Previously, obstetricians worldwide have strongly avoided the use of codeine-class drugs, opting instead for non-steroidal anti-inflammatory drugs (NSAIDs) or stronger synthetic opioids, leading to a renewed evaluation of the risks of ulcers and side effects associated with these alternative medications.
At the same time, the clinical necessity and cost-effectiveness of codeine metabolism screening tests based on CYP2D6 genotypes, developed by clinical diagnostic companies, must also be reassessed. If the exaggerated risk figures resulting from data manipulation are normalized, clinicians will gain the rational discretion to design optimized, personalized pain management regimens for individual mothers based on actual accumulated precise safety profiles, rather than excluding medications out of fear.